{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:45Z","timestamp":1787014365505,"version":"build-2736575974"},"reference-count":152,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Bruton's Tyrosine Kinase (BTK) is a cytoplasmic kinase essential for B cell\u2010mediated signalling,\u00a0yet has also received recent recognition as a direct regulator of myeloid cell function. Beyond its established role in B cell malignancies, BTK influences receptor\u2010driven activation in monocytes, macrophages, microglia, granulocytes, and other organ\u2010specific macrophages by influencing key molecular pathways involved in phagocytosis, inflammatory\u2010mediated signalling, and cell metabolism (e.g., NF\u03baB, STAT3, and NLRP3). BTK inhibitors (BTKis) were initially developed and approved to treat B cell\u2010related cancers, however, they have also demonstrated significant therapeutic\/clinical efficacy in autoimmune, allergic, and immune\u2010driven neuroinflammatory disorders, including rheumatoid arthritis, IgA nephropathy, multiple sclerosis, and chronic spontaneous urticaria. This review specifically addresses, compares, and summarises how BTK inhibition within distinct myeloid\u2010derived cell subsets alters inflammatory\u2010related phenotypes and functions within these cells. Together, providing cell\u2010specific insights into BTK as a central regulator of innate immunity and myeloid cell function may help generate significant translational potential for BTKis in multiple inflammatory\u2010mediated diseases.<\/jats:p>","DOI":"10.1111\/imm.70126","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:42:31Z","timestamp":1773024151000},"page":"545-560","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bruton's Tyrosine Kinase\u2014Going Beyond the B Cell"],"prefix":"10.1111","volume":"178","author":[{"given":"Rochelle Y.","family":"Benoit","sequence":"first","affiliation":[{"name":"Division of Biomedical Sciences Faculty of Medicine, Memorial University of Newfoundland  St. John's Newfoundland and Labrador Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Loshi","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences Faculty of Medicine, Memorial University of Newfoundland  St. John's Newfoundland and Labrador Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-435X","authenticated-orcid":false,"given":"Craig S.","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences Faculty of Medicine, Memorial University of Newfoundland  St. John's Newfoundland and Labrador Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.321"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.118622"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.6.3635"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707682200"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.316"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80417-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.12.3396"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab231"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9579-6"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22803"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006765"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942"},{"key":"e_1_2_7_18_1","first-page":"66","article-title":"Imbruvica (Ibrutinib), First\u2010In\u2010Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients With Relapsed Chronic Lymphocytic Leukemia","volume":"8","author":"Raedler L. A.","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000497356"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721990553"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.09.005"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab045"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.723967"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1490"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16836"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128322"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11782"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02158"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169927"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-22-0572"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0463-3"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040817"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2019.05.030"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03497-1"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1659704"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15182"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1308-0"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102960"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010355"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09839-0"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109920"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107123"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176142"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01656-1"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111903"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13166"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.987"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1339874"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02730-0"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13240"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2400045"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae160"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03187-4"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.07.003"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/JPER.18-0334"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001323"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02877-9"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01537-w"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001552"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32010"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02997-2"},{"key":"e_1_2_7_63_1","volume-title":"Rilzabrutinib, a Potent and Selective Bruton Tyrosine Kinase Inhibitor, Suppresses Reactive Oxygen Species Production and CD11b Activation in Human Eosinophils","author":"Shade K.\u2010T.","year":"2024"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2019.100201"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2100063"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14090"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0039OC"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00089-9"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2017.06.003"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181782"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7203"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.687251"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524583"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.011"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00674-21"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gdata.2016.02.010"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108710"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8767529"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.03.140"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00234.2013"},{"key":"e_1_2_7_81_1","first-page":"361","article-title":"Effects of Bruton's Tyrosine Kinase on the Proliferation and Differentiation of Osteoclasts","volume":"37","author":"Zhang H.","year":"2019","journal-title":"Hua Xi Kou Qiang Yi Xue Za Zhi"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9706-z"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175961"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06342-5"},{"key":"e_1_2_7_85_1","first-page":"181","article-title":"Defective Fc\u2010, CR1\u2010 and CR3\u2010Mediated Monocyte Phagocytosis and Chemotaxis in Common Variable Immunodeficiency and X\u2010Linked Agammaglobulinemia Patients","volume":"13","author":"Amoras A. L.","year":"2003","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.01.037"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424907112"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02908-5"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.037"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1235"},{"key":"e_1_2_7_91_1","first-page":"D917","article-title":"Bruton Tyrosine Kinase (BTK) in X\u2010Linked Agammaglobulinemia (XLA)","volume":"5","author":"Vihinen M.","year":"2000","journal-title":"Frontiers in Bioscience"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000313"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02733-2"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15778"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41275"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00174-7"},{"key":"e_1_2_7_97_1","unstructured":"H.\u2010L.Roche \u201cA Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance) \u201d2025 ClinicalTrials.gov."},{"key":"e_1_2_7_98_1","unstructured":"H.\u2010L.Roche \u201cA Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid) \u201d2025."},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01537-w"},{"key":"e_1_2_7_100_1","article-title":"Everest Medicines Presents Positive REsults From Phase 1b\/2a Clinical Trial of EVER001 for Primary Mebranous Nephropathy at ERA 2025","author":"Newswire A.","year":"2025","journal-title":"Chronical Journal"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241234783"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415985"},{"key":"e_1_2_7_104_1","unstructured":"Sanofi \u201cPrimary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS) \u201d2026 ClinicalTrials.gov."},{"key":"e_1_2_7_105_1","unstructured":"Biopharma S.P \u201cStudy to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA3) \u201d2025 ClinicalTrials.gov."},{"key":"e_1_2_7_106_1","unstructured":"Biopharma \u201cS.P. A Study of PRN1008 in Patients with Pemhigus \u201d2023 ClinicalTrials.gov."},{"key":"e_1_2_7_107_1","unstructured":"Pharmaceuticals N. A \u201cPhase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1\u2010Antihistamines (REMIX\u20102) \u201d2025 ClinicalTrials.gov."},{"key":"e_1_2_7_108_1","unstructured":"Novartis \u201cEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis \u201dClinicalTrials.gov 2025."},{"key":"e_1_2_7_109_1","unstructured":"Novartis \u201cEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis \u201dClinicalTrials.gov 2025."},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.07.002"},{"key":"e_1_2_7_111_1","unstructured":"Co. B. I. P. T \u201cA Phase 2 Study of Orelabrutinib in Patients With Relapsing\u2010Remitting Multiple Sclerosis \u201dClinicalTrials.gov 2023."},{"key":"e_1_2_7_112_1","unstructured":"Beijing InnoCare Pharma Tech Co \u201cA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis \u201dClinicalTrials.gov 2025."},{"key":"e_1_2_7_113_1","unstructured":"Biogen \u201cA Study to Learn about the safety of BIIB091 and Its effect on brain inflammation when taken alone or with Diroximel Fumarate (DRF) in adults with Relapsing forms of Multiple Sclerosis \u201dClinicalTrials.gov 2025."},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01331-9"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.11064"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204143"},{"key":"e_1_2_7_117_1","unstructured":"W.WilsonandL. M.Staud \u201cStudy Identifies Potential Approach to Treat Severe Respiratory Distress in Patients With COVID\u201019. National Cancer Institute \u201d2020."},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737943"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/immhor\/vlaf023"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-55529-9_16"},{"key":"e_1_2_7_122_1","volume-title":"BTK Expression in Microglia","author":"Atlas P.","year":"2025"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12564"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01257-z"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117172"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.018"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121804119"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01590-1"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00938-2"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146779"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.05.055"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01887-1"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264128"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy296"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.035"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2018"},{"key":"e_1_2_7_137_1","first-page":"7","article-title":"The Influence of Heparin on Histamine Level in Plasma During the Early Reaction Phase of Asthma","volume":"97","author":"Antczak\u2010Marczak M.","year":"1997","journal-title":"Polskie Archiwum Medycyny Wewn\u0119trznej"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204271"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107172"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138448"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.107037"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23433"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfl173"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.10.024"},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v16.i5.269"},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S326627"},{"key":"e_1_2_7_147_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000749"},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.001"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005621"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203287"},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_2_7_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"}],"container-title":["Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imm.70126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imm.70126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imm.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:20:37Z","timestamp":1783012837000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imm.70126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/imm.70126"],"URL":"https:\/\/doi.org\/10.1111\/imm.70126","archive":["Portico"],"relation":{},"ISSN":["0019-2805","1365-2567"],"issn-type":[{"value":"0019-2805","type":"print"},{"value":"1365-2567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"2025-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}